Zealand Pharma A/S (ZEAL.CO)
Develops injectable medicines for digestive and metabolic diseases like severe low blood sugar
305.90+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-6.6%
The outlook
Zealand Pharma trades near its 52-week low, with analyst consensus at "Buy" and an average price target around 45% above current levels. The stock shows mixed momentum relative to its moving averages, while the low trailing P/E of 3.4 reflects its early-stage biotech profile. Overall sentiment is neutral, balancing bullish analyst views against uncertain near-term technicals.
What’s behind the score
Analyst consensusBuy — 2.3 avg of 14 analysts
Price trendMixed vs its moving averages
52-week range22% of the way from its 52-week low to high
Price targetAvg target +45% vs current price
Analyst price target
~12-month · 14 analysts444.36average target+45.3% vs now
Now 305.90
Low 300.00High 745.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$21.05B
52-wk high
556.00
52-wk low
233.50
50-day avg
296.81
200-day avg
374.79
Trailing P/E
3.4